Tirzepatide 5-Day vs 7-Day Dosing: What the Tracking Data Says
5 min read
CTO & Co-Founder of miora. Stanford Biodesign, ex-Tesla.
Tirzepatide has a half-life of approximately five days, which is the basis for the weekly dosing approved by the FDA. A portion of the community runs a 5-day cadence instead, citing flatter side-effect curves and more consistent appetite suppression. This is what the tracking data actually says about the tradeoffs - and what to log if you are running one cadence and considering the other.
Topics on this page
Tirzepatide half-life is approximately 5 days. Weekly dosing produces a defined trough at day 6-7; 5-day cadence largely eliminates the trough.
5-day cadence increases monthly exposure to tirzepatide by approximately 40% (6 doses per month vs 4.3). The cost implications and the side-effect implications follow.
The day-by-day side-effect log shows the curve compression on 5-day cadence: less of a peak, more of a flat baseline. Whether that is better depends on the user.
Tirzepatide's pharmacokinetic profile - a half-life of roughly five days - is what supports the FDA-approved weekly dosing schedule. By Day 7, plasma levels have dropped meaningfully, and for some users this translates into perceptible 'day 6-7 dropoff' where appetite suppression weakens before the next dose. A portion of the community has experimented with a 5-day dosing cadence specifically to address this. The compound is the same; the schedule is the variable. This guide is the structured comparison of what tracking data shows about each approach.
Tirzepatide has a half-life of approximately 5 days, established in the FDA-approved labeling. The half-life is the time for plasma concentration to fall to half its peak; after 5 half-lives (about 25 days) the drug is essentially eliminated.
The weekly dosing schedule produces a steady-state plasma concentration with a trough at day 6-7 (right before the next injection) and a peak in the 24-72 hours after each injection. The trough is meaningful: by day 6, plasma tirzepatide has dropped roughly 60% from peak. For users with a sensitive receptor response, this can translate into perceptible weakening of appetite suppression in the last day or two of each week.
5-day dosing changes the math. At a 5-day interval, the trough is less pronounced (plasma drops only 50% from peak) and the steady-state is roughly 40% higher because you are dosing more frequently. Some users find this produces flatter appetite suppression and a less spiky side-effect curve. Others find the higher exposure produces more cumulative side effects.
None of this is hypothetical for the active community; thousands of users are running each schedule. The tracking data is the operative comparison.
Mapped to days post-injection, the typical side-effect curves on each schedule:
Weekly (day 0 to day 7). Day 0: injection. Day 1-2: peak nausea and fatigue. Day 3: recovery starting. Day 4-5: baseline. Day 6-7: pre-injection trough, sometimes accompanied by appetite return.
5-day cadence (day 0 to day 5). Day 0: injection. Day 1-2: smaller nausea peak (because the previous dose's plasma level still provides some adaptation). Day 3: near baseline. Day 4-5: stable, with another injection coming.
On 5-day cadence the day-1-2 peak is typically lower in intensity but the user spends a higher percentage of the week at non-baseline. The 'down days' are smaller; the 'baseline days' are fewer.
For tracking, the daily 1-to-5 rubric captures the curve on either schedule. The weekly summary maps the curve to whichever interval is running and surfaces the cumulative side-effect burden.
Weekly dosing produces 52 doses per year. 5-day cadence produces approximately 73 doses per year (every 5 days × 365.25 / 5 = 73). The monthly exposure difference is about 40% higher on the 5-day schedule.
Practical implications:
Cost. 40% more product. For users on branded Mounjaro or Zepbound, the prescription is supplied weekly; running 5-day cadence requires either more prescriptions or splitting weekly pens (which is off-label and requires clinician oversight). For users on compound tirzepatide, the vial math changes proportionally.
Side-effect cumulative burden. The higher steady-state plasma concentration means the user spends more time at higher exposure. Whether this produces more side effects depends on individual response.
Lab exposure. Quarterly cardiometabolic labs become more important. Higher cumulative exposure may surface signals that weekly dosing does not.
Insurance. Insurance plans are built around the FDA-approved weekly schedule. 5-day cadence is off-label; coverage may not extend to the higher dispensing frequency.
None of these is necessarily a deal-breaker. The point is that the schedule choice has consequences beyond the side-effect curve.
Based on the community tracking data and clinician reports, certain user profiles tend to benefit from 5-day cadence and others tend not to.
Users who often benefit:
Users reporting strong appetite return at day 6-7 on weekly dosing (the trough effect).
Users with spiky nausea curves at the day-1-2 peak that significantly compromise function.
Users at the maximum maintenance dose on weekly who still want incrementally more appetite suppression without escalating dose further.
Users with healthcare access (clinician willing to manage off-label, supply chain capable of higher dispensing).
Users who often do not benefit:
Users with already-flat side-effect curves on weekly dosing.
Users early in titration; the schedule complexity is unnecessary before the user knows how their individual curve looks on weekly.
Users with cost-sensitive supply (40% more product is substantial).
Users whose clinician is not comfortable with off-label dose schedules.
The data that determines which group you are in is the daily side-effect log. A user who has been on weekly tirzepatide for 8+ weeks with consistent logging has the data to make the conversation with the prescriber productive.
The miora daily check is the same on either schedule: nausea, fatigue, GI changes, hydration, protein, mood. The difference is in how the curve is mapped.
Weekly dosing. The weekly summary maps the curve to days 0-6 post-injection. The trough days (5-6) are explicitly noted. Cross-references against appetite or food-noise score if logged.
5-day cadence. The summary maps the curve to days 0-4 post-injection. The shorter cycle is captured. The cumulative monthly exposure and the weekly side-effect burden are both surfaced.
Transitioning between schedules. If a clinician approves a switch from weekly to 5-day (or back), miora handles it as a continuation. The baseline data from the prior schedule is preserved as the comparison.
For users running compound tirzepatide on 5-day cadence, the dose math is the same as weekly compound (units per dose based on vial concentration); the inventory just decrements faster.
The honest reality of 5-day tirzepatide cadence is that the long-term safety and outcome data does not exist. The RCT data (SURMOUNT-1 and follow-on trials) all use weekly dosing. The 5-day cadence data is real-world off-label use, primarily community-tracked.
Open questions that the tracking data does not yet answer:
Cardiometabolic markers across 5-day vs weekly. Whether the higher exposure produces meaningfully different lipid, HbA1c, or hsCRP trajectories.
Long-term receptor adaptation. Whether more frequent dosing produces different receptor desensitization patterns over years.
Discontinuation rebound. Whether the rebound effects when stopping differ.
Body composition outcomes. Whether the protein and lean-mass outcomes differ at comparable weight-loss trajectories.
Users running off-label schedules contribute to the answer when they track diligently and share data with their clinicians. The tracking discipline is the contribution.
5-day cadence users should flag specific signals to their prescriber that may not warrant the same attention on weekly:
Cumulative side-effect burden. If the daily rubric shows non-baseline scores more than 70% of days, the cumulative burden may exceed the appetite-suppression benefit.
Resting HR trending up. Higher exposure may surface cardiometabolic shifts. Track daily.
Lab shifts. Quarterly labs may show different trends than on weekly; flag any meaningful change.
Loss rate faster than 2.5% body weight per month. The higher exposure can produce aggressive loss; body composition check warranted.
Mood drift. Higher cumulative GLP-1 exposure may amplify mood-circuit effects. Track the six-dimension rubric.
The clinician conversation about whether to continue 5-day cadence, return to weekly, or modify dose belongs with the prescriber. miora's data makes the conversation specific.
Three boundaries.
This guide does not recommend 5-day cadence or weekly dosing. The FDA-approved schedule is weekly; 5-day cadence is off-label and requires clinician oversight comfortable with the schedule. The decision is a clinician conversation, not a community decision.
The guide does not recommend a specific dose on either schedule. Dose escalation on 5-day cadence is more conservative than on weekly because the cumulative exposure is higher; the specific titration belongs with your prescriber.
The guide does not source tirzepatide on any schedule. miora does not source any compound; insurance coverage and access are between you and your prescriber and pharmacy. This content is for informational purposes only and is not medical advice. Tirzepatide requires prescription and clinician supervision regardless of dosing schedule.
109
